Cardinal Health (NYSE:CAH) Azioni

Cardinal Health

Cardinal Health is one of three leading pharmaceutical wholesalers in the US, engaged in sourcing and distributing of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. Cardinal, Cencora, and McKesson hold well over 90% of the US pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.

Long Ideas

News

Markets

Media

Trading Ideas

LMND

Il noto analista di Wall Street mette in guardia gli investitori riguardo a un&#39;azione che ha registrato un aumento eccessivo.

Jim Cramer: questo titolo è &#34;salito troppo… Bisogna lasciarlo scendere&#34;

Short Ideas

Pre-Market Outlook

CPRX

VRNA

Scopriamo i 3 titoli sanitari che potrebbero affrontare un crollo a causa di indicatori di mercato e RSI elevati.

Scopri i 3 titoli sanitari che potrebbero crollare ad agosto

Earnings

CSCO

OUST

SERV

Scopri i 5 titoli azionari da tenere d&#39;occhio oggi, 14 agosto 2024, con aggiornamenti su Brinker, Cisco e altri.

Pre-market: 5 titoli da monitorare oggi, 14 agosto 2024

Cardinal Health Inc

CARRIER ALLIANCE HLDGS by Carrier Alliance Holdings, Inc.

Carrier Alliance Holdings Inc

CELESTIAL ASIA SECS NEW by Celestial Asia Secs Holdings Ltd.

Celestial Asia Securities Holdings Ltd

Caro Holdings Inc

EVOLUTION MINING LTD ORD by Evolution Mining Ltd.

Evolution Mining Ltd

Cardinal Health's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) short percent of float has fallen 10.53% since its last report. The company recently reported that it has 5.33 million shares sold short, which is 2.89% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.32 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Cardinal Health Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748361629_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Cardinal Health has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Cardinal Health's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Cardinal Health's peer group average for short interest as a percentage of float is 4.46%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

What's Driving the Market Sentiment Around Cardinal Health?

Rep. Marjorie Taylor Greene (R-Ga.) has been actively buying stocks in 2025 and is back with more than a dozen more trades less than two weeks after <a href="https://www.benzinga.com/politics/25/05/45272436/marjorie-taylor-greene-goes-stock-shopping-again-here-are-50-stocks-the-congresswoman-bought">her last disclosure.</a>
Here's the latest transactions made by the congresswoman in May.
What Happened: Greene ranks 24th among the <a href="https://www.benzinga.com/25/01/42860759/10-best-stock-traders-in-congress-in-2024-where-do-nancy-pelosi-pete-sessions-susan-collins-marjorie-taylor-greene-rank">best-performing members</a> of Congress based on their trades in 2024. The Congresswoman gained 30.2% for the year, outperforming the S&amp;P 500 gain of 24.9%.
Greene recently disclosed over 50 new stock trades in early May, which came on top of some potentially perfectly timed trades that happened before President Donald Trump&#8217;s pause of tariffs, which sent the market soaring.
Here are Greene&#8217;s most recent trades made on May 14, per the <a href="https://www.benzinga.com/gov-trades/members/marjorie-taylor-greene" target="_blank" rel="noreferrer noopener">Benzinga Government Trades page</a>. All purchases made were listed as between $1,001 to $15,000 unless otherwise indicated.
<ul class="wp-block-list">
<li>UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>): $15,000 to $50,000</li>
<li>Alphabet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>)</li>
<li>Amgen Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>)</li>
<li>Advanced Micro Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>)</li>
<li>Blackstone (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BX#NYSE">BX</a>)</li>
<li>Cardinal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>)</li>
<li>Chevron Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>)</li>
<li>Corning Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLW#NYSE">GLW</a>)</li>
<li>Dollar General Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DG#NYSE">DG</a>)</li>
<li>Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>)</li>
<li>Impinj Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PI#NASDAQ">PI</a>)</li>
<li>MercadoLibre Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MELI#NASDAQ">MELI</a>): $15,000 to $50,000</li>
<li>Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>)</li>
<li>Morgan Stanley (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MS#NYSE">MS</a>)</li>
<li>Netflix Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>)</li>
<li>NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)</li>
<li>ServiceNow (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>)</li>
<li>Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)</li>
<li>The Hershey Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HSY#NYSE">HSY</a>)</li>
</ul>
Greene also disclosed buying an additional $1,000 to $15,000 in UnitedHealth stock on May 16. The Congresswoman also disclosed buying $100,000 to $250,000 in US Treasury Bills on May 16.
Greene has bought $2.82 million in stocks in 2025 according to <a href="https://www.quiverquant.com/congresstrading/politician/Marjorie%20Taylor%20Greene-G000596">data </a>from Quiver Quantitative with only $75,000 in stock sales. The Congresswoman bought $3.89 million in stocks in 2024 with $65,000 in sales.
Read Also: <a href="https://www.benzinga.com/politics/25/05/45449720/speaker-johnson-backs-congressional-stock-trading-ban-ruined-by-a-few-bad-actors">Speaker Johnson Backs Congressional Stock Trading Ban: Ruined By &#8216;A Few Bad Actors&#8217;</a>
Why It&#8217;s Important: Members of Congress are allowed to buy and sell stocks as long as they properly disclose the transaction.
The process has drawn scrutiny from the public and retail investors as members of Congress could have inside information and time their trades accordingly. Committee assignments in particular, often draw red flags from investors.
Greene serves on the House Committee on Oversight and Accountability and the House Committee on Homeland Security with several subcommittee appointments. The congresswoman&#8217;s past trade in technology and cybersecurity stocks has drawn attention with her role within Homeland Security.
Greene's past trades of Palantir Technologies and a<a href="https://www.benzinga.com/25/03/44255172/marjorie-taylor-greene-buys-more-bitcoin-etf-shares-ahead-of-trumps-strategic-reserve-executive-order" target="_blank" rel="noreferrer noopener">&nbsp;Bitcoin ETF&nbsp;</a>have drawn criticism along with the timing of her trades, as she is a close ally to President&nbsp;Donald Trump.
When asked previously about buying stocks earlier this year that soared days later after Trump announced a pause to tariffs, Greene<a href="https://www.benzinga.com/politics/25/04/44852406/marjorie-taylor-greene-brushes-off-stock-buying-criticism-says-portfolio-manager-bought-the-dip" target="_blank" rel="noreferrer noopener">&nbsp;brushed aside the criticism.</a>
"I think that criticism is laughable. President Trump has been talking about tariffs for decades," Greene told reporters when asked about the trades at a recent town hall event in Georgia in a clip&nbsp;<a href="https://x.com/unusual_whales/status/1912456434081480777" target="_blank" rel="noreferrer noopener">shared&nbsp;</a>by Unusual Whales. The congresswoman used the opportunity to boast about her stock performance, which ranked her as one of the top trading members of Congress in 2024.
"I don't place my buys and sells,&#8221; Greene said, citing an agreement she has with her portfolio manager, who handles all the buying and selling of stocks. "He did a great job. Guess what he did. He bought the dip. And that's what anybody that has financial sense does.&#8221;
Greene also said her portfolio manager did not have inside information, everything was public and a potential tariff pause wasn't a secret.
Sen.&nbsp;Josh Hawley&nbsp;(R-Mo.) has reintroduced legislation that would ban members of Congress from trading or holding individual stocks.
The bill is known as the Preventing Elected Leaders from Owning Securities and Investments Act, or PELOSI Act based on the first letter of each of the main words. The name takes aim at the congresswoman and former Speaker of the House&nbsp;Nancy Pelosi&nbsp;(D-Calif.). &nbsp;
"Members of Congress should be fighting for the people they were elected to serve — not day trading at the expense of their constituents," Hawley&nbsp;<a href="https://www.hawley.senate.gov/hawley-reintroduces-pelosi-act-to-ban-congress-from-trading-stocks/" target="_blank" rel="noreferrer noopener">said</a>. "Americans have seen politician after politician turn a profit using information not available to the general public."
Hawley said the bill will help "restore Americans' trust in our nation's legislative body."
Hawley's bill is being reintroduced as President&nbsp;Donald Trump&nbsp;<a href="https://time.com/7280114/donald-trump-2025-interview-transcript/" target="_blank" rel="noreferrer noopener">said&nbsp;</a>he would support such a ban.
"Well, I watched Nancy Pelosi get rich through insider information, and I would be okay with it. If they send it to me, I would do it," Trump told TIME.
Trump said he would sign the ban if the bill passes Congress.
While Pelosi makes headlines for her trades, it's important to remember that<a href="https://www.benzinga.com/politics/25/04/44852406/marjorie-taylor-greene-brushes-off-stock-buying-criticism-says-portfolio-manager-bought-the-dip" target="_blank" rel="noreferrer noopener">&nbsp;it is both Republican</a>&nbsp;and Democratic members of Congress who are profiting from buying and selling stocks and options while in office, with some trades coming with questionable timing or having a connection to committees they serve on.
In 2024, a list of the top-performing traders in Congress included six Republicans and four Democrats.
Did You Know?
<ul class="wp-block-list">
<li>Congress Is Making Huge Investments.&nbsp;<a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent052025" target="_blank" rel="noreferrer noopener">Get Tips On What They Bought And Sold With Our Easy-to-Use Tool</a></li>
</ul>
<figure class="wp-block-image size-large"><a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent052025"><img loading="lazy" decoding="async" width="1024" height="330" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/20135920/Picture1-5-1024x330.png" alt="" class="wp-image-921773" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/20135920/Picture1-5-1024x330.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/20135920/Picture1-5-300x97.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/20135920/Picture1-5-768x248.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/20135920/Picture1-5.png 1430w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Image: Shutterstock

Politics

AMGN

GOOG

MELI

NFLX

NVDA

TSLA

Marjorie Taylor Greene Goes Shopping For Tesla, Netflix, UnitedHealth And More: 19 Stocks The Congresswoman Bought

<a href="https://www.cnbc.com/2025/05/12/trump-drug-pricing-order-most-favored-nation.html">https://www.cnbc.com/2025/05/12/trump-drug-pricing-order-most-favored-nation.html</a>
&nbsp;
<ul>
<li>President Donald Trump will revive a controversial policy that aims to slash drug costs by tying the amount the government pays for some medicines to lower prices abroad, White House officials said.</li>
<li>The order is a blow to the pharmaceutical industry, which is already bracing for Trump&#39;s planned tariffs on prescription drugs.</li>
<li>It is Trump&#39;s latest effort to try to rein in U.S. prescription drug prices, which are two to three times higher on average than those in other developed nations.</li>
</ul>
&nbsp;

MRNA

'Trump To Sign Order To Cut Some U.S. Drug Prices To Match Those Abroad' - CNBC

Rep. Marjorie Taylor Greene (R-Ga.) has been actively buying stocks in 2025, including transactions that may have been perfectly timed<a href="https://www.benzinga.com/politics/25/04/44852406/marjorie-taylor-greene-brushes-off-stock-buying-criticism-says-portfolio-manager-bought-the-dip"> during a market dip.</a>
Here's the latest transactions made by the congresswoman in early May.
What Happened: Greene was ranked as the 24th best-performing member of Congress based on their trades in 2024. The Congresswoman gained 30.2% for the year, <a href="https://www.benzinga.com/25/01/42860759/10-best-stock-traders-in-congress-in-2024-where-do-nancy-pelosi-pete-sessions-susan-collins-marjorie-taylor-greene-rank">outperforming the S&amp;P 500 </a>gain of 24.9%.
With new trades placed throughout the early months of 2025, Greene could see huge returns again during the year.
Here are her most recent trades made on May 5, as shown on the <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent050725">Benzinga Government Trades page</a>. All purchases made were listed as between $1,001 to $15,000 unless otherwise indicated.
<ul>
<li>Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>)</li>
<li>AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>)</li>
<li>Adobe Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADBE#NASDAQ">ADBE</a>)</li>
<li>Applied Materials (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>)</li>
<li>Advanced Micro Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>)</li>
<li>Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>)</li>
<li>American Express (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXP#NYSE">AXP</a>)</li>
<li>Boeing Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>)</li>
<li>Bank of America (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>)</li>
<li>BHP Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHP#NYSE">BHP</a>)</li>
<li>BP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BP#NYSE">BP</a>)</li>
<li>Berkshire Hathaway Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>)</li>
<li>Blackstone Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BX#NYSE">BX</a>)</li>
<li>Cardinal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>)</li>
<li>Caterpillar (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAT#NYSE">CAT</a>)</li>
<li>Cummins Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMI#NYSE">CMI</a>)</li>
<li>Chevron Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>)</li>
<li>Dell Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>)</li>
<li>Digital Realty Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DLR#NYSE">DLR</a>)</li>
<li>Duke Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DUK#NYSE">DUK</a>)</li>
<li>Devon Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DVN#NYSE">DVN</a>)</li>
<li>FedEx Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDX#NYSE">FDX</a>)</li>
<li>Frontline PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FRO#NYSE">FRO</a>)</li>
<li>Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>): two separate purchases of $1,001 to $15,000</li>
<li>Corning Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLW#NYSE">GLW</a>)</li>
<li>Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>)</li>
<li>Goldman Sachs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>)</li>
<li>Home Depot (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HD#NYSE">HD</a>)</li>
<li>The Hershey Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HSY#NYSE">HSY</a>)</li>
<li>Intel Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>)</li>
<li>Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>)</li>
<li>JPMorgan Chase (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>)</li>
<li>Kinder Morgan (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMI#NYSE">KMI</a>)</li>
<li>Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>)</li>
<li>MercadoLibre (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MELI#NASDAQ">MELI</a>)</li>
<li>Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>)</li>
<li>Merck Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>)</li>
<li>Morgan Stanley (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MS#NYSE">MS</a>)</li>
<li>Microsoft Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>)</li>
<li>NextEra Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEE#NYSE">NEE</a>)</li>
<li>ServiceNow Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NASDAQ">NOW</a>)</li>
<li>Norfolk Southern (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NSC#NYSE">NSC</a>): two separate purchases of $1,001 to $15,000</li>
<li>NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)</li>
<li>Old Dominion Freight Line (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODFL#NASDAQ">ODFL</a>)</li>
<li>Occidental Petroleum (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXY#NYSE">OXY</a>): two separate purchases of $1,001 to $15,000</li>
<li>Palo Alto Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANW#NASDAQ">PANW</a>)</li>
<li>Paychex Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAYX#NASDAQ">PAYX</a>)</li>
<li>Impinj Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PI#NASDAQ">PI</a>)</li>
<li>Qualcomm Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>)</li>
<li>Starbucks Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>)</li>
<li>Charles Schwab Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHW#NYSE">SCHW</a>)</li>
<li>Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)</li>
<li>United Parcel Service (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UPS#NYSE">UPS</a>)</li>
<li>Visa Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>)</li>
<li>Walmart Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>)</li>
</ul>
In total, that's more than 50 different stocks bought and disclosed by Greene in the latest filing. Based on the purchase range of $1,001 to $15,000, this would make the transaction range over $50,000 and up to more than $800,000.
Read Also: <a href="https://www.benzinga.com/politics/25/04/45077654/bill-named-after-nancy-pelosi-could-ban-congress-members-from-trading-stocks-what-you-need-to-know-about-the-pelosi-act">Bill Named After Nancy Pelosi Could Ban Congress Members From Trading Stocks: What You Need To Know About The &#8216;PELOSI&#8217; Act</a>
Why It's Important: Members of Congress are allowed to buy and sell stocks as long as they properly disclose the transaction.
The process has drawn scrutiny from the public and retail investors as members of Congress could have inside information and time their trades accordingly. Committee assignments in particular, often draw red flags from investors.
Greene serves on the House Committee on Oversight and Accountability and the House Committee on Homeland Security with several subcommittee appointments. The congresswoman's past trade in technology and cybersecurity stocks has drawn attention with her role within Homeland Security.
Greene&#8217;s past trades of Palantir Technologies and a<a href="https://www.benzinga.com/25/03/44255172/marjorie-taylor-greene-buys-more-bitcoin-etf-shares-ahead-of-trumps-strategic-reserve-executive-order"> Bitcoin ETF </a>have drawn criticism along with the timing of her trades, as she is a close ally to President Donald Trump. 
When asked previously about buying stocks earlier this year that soared days later after Trump announced a pause to tariffs, Greene<a href="https://www.benzinga.com/politics/25/04/44852406/marjorie-taylor-greene-brushes-off-stock-buying-criticism-says-portfolio-manager-bought-the-dip"> brushed aside the criticism.</a>
&#8220;I think that criticism is laughable. President Trump has been talking about tariffs for decades,&#8221; Greene told reporters when asked about the trades at a recent town hall event in Georgia in a clip <a href="https://x.com/unusual_whales/status/1912456434081480777" target="_blank" rel="noreferrer noopener">shared </a>by Unusual Whales. The congresswoman used the opportunity to boast about her stock performance, which ranked her as one of the top trading members of Congress in 2024.
&#8220;I don&#8217;t place my buys and sells," Greene said, citing an agreement she has with her portfolio manager, who handles all the buying and selling of stocks. &#8220;He did a great job. Guess what he did. He bought the dip. And that&#8217;s what anybody that has financial sense does."
Greene also said her portfolio manager did not have inside information, everything was public and a potential tariff pause wasn&#8217;t a secret.
Sen. Josh Hawley (R-Mo.) has reintroduced legislation that would ban members of Congress from trading or holding individual stocks.
The bill is known as the Preventing Elected Leaders from Owning Securities and Investments Act, or PELOSI Act based on the first letter of each of the main words. The name takes aim at the congresswoman and former Speaker of the House Nancy Pelosi (D-Calif.).  
&#8220;Members of Congress should be fighting for the people they were elected to serve — not day trading at the expense of their constituents,&#8221; Hawley&nbsp;<a href="https://www.hawley.senate.gov/hawley-reintroduces-pelosi-act-to-ban-congress-from-trading-stocks/" target="_blank" rel="noreferrer noopener">said</a>. &#8220;Americans have seen politician after politician turn a profit using information not available to the general public.&#8221;
Hawley said the bill will help &#8220;restore Americans&#8217; trust in our nation&#8217;s legislative body.&#8221;
Hawley&#8217;s bill is being reintroduced as President&nbsp;Donald Trump&nbsp;<a href="https://time.com/7280114/donald-trump-2025-interview-transcript/" target="_blank" rel="noreferrer noopener">said&nbsp;</a>he would support such a ban.
&#8220;Well, I watched Nancy Pelosi get rich through insider information, and I would be okay with it. If they send it to me, I would do it,&#8221; Trump told TIME.
Trump said he would sign the ban if the bill passes Congress.
While Pelosi makes headlines for her trades, it&#8217;s important to remember that<a href="https://www.benzinga.com/politics/25/04/44852406/marjorie-taylor-greene-brushes-off-stock-buying-criticism-says-portfolio-manager-bought-the-dip" target="_blank" rel="noreferrer noopener">&nbsp;it is both Republican</a>&nbsp;and Democratic members of Congress who are profiting from buying and selling stocks and options while in office, with some trades coming with questionable timing or having a connection to committees they serve on.
In 2024, a list of the top-performing traders in Congress included six Republicans and four Democrats.
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent050725">Get Tips On What They Bought And Sold With Our Easy-to-Use Tool</a></li>
</ul>
<figure class="wp-block-image size-large"><a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent050725"><img loading="lazy" decoding="async" width="1024" height="330" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07181256/Picture1-1-1024x330.png" alt="" class="wp-image-906796" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07181256/Picture1-1-1024x330.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07181256/Picture1-1-300x97.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07181256/Picture1-1-768x248.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07181256/Picture1-1.png 1430w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Photo: Shutterstock

Government

AAPL

ABBV

ADBE

AMAT

AMZN

DELL

GILD

INTC

MSFT

ODFL

PANW

PAYX

QCOM

SBUX

SCHW

Marjorie Taylor Greene Goes Stock Shopping Again: Here Are 50+ Stocks The Congresswoman Bought

<a href="https://www.washingtonpost.com/politics/2025/05/05/trump-presidency-news/#link-ACU42F27X5AMNOGEOOY7YDJOFE">https://www.washingtonpost.com/politics/2025/05/05/trump-presidency-news/#link-ACU42F27X5AMNOGEOOY7YDJOFE</a>
President Donald Trump will sign an executive order Monday to streamline regulations surrounding pharmaceutical manufacturing in the United States, according to two White House officials who spoke on the condition of anonymity to describe plans that have not been made public.
The order to incentivize domestic drug manufacturing comes ahead of possible <a href="https://www.washingtonpost.com/business/2025/04/10/tariffs-pharmaceuticals-us-drugs-cost/">tariffs on pharmaceuticals</a> — a policy that's on hold, for now, pending an investigation by the Commerce Department to determine whether importing pharmaceuticals is a threat to national security. That Section 232 investigation could be completed this summer, one of the officials said Monday.
But regardless of whether the Trump administration puts tariffs on prescription drugs, Monday's executive order seeks to incentivize more domestic manufacturing of medications.

Biotech

General

BNTX

'Trump To Sign Order To Encourage Domestic Drug Manufacturing' - Washington Post

Morgan Stanley analyst Erin Wright maintains Cardinal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) with a Overweight and raises the price target from $142 to $166.

Price Target

Analyst Ratings

Morgan Stanley Maintains Overweight on Cardinal Health, Raises Price Target to $166

UBS analyst Kevin Caliendo maintains Cardinal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) with a Buy and raises the price target from $160 to $170.

UBS Maintains Buy on Cardinal Health, Raises Price Target to $170

Baird analyst Eric Coldwell maintains Cardinal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) with a Outperform and raises the price target from $156 to $170.

Baird Maintains Outperform on Cardinal Health, Raises Price Target to $170

Cardinal Health Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) on Thursday&nbsp;reported third-quarter 2025 adjusted EPS of $2.35, up 13% year over year, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $2.17</a>.
Sales remained flat at $54.9 billion, missing the consensus of $55.35 billion. Adjusted operating earnings increased 21% to&nbsp;$807 million.
Third-quarter sales for the Pharmaceutical and Specialty Solutions segment remained <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/n45129354/cardinal-health-reports-third-quarter-fiscal-year-2025-results-and-raises-fiscal-year-2025-outlook" rel="noreferrer noopener">unchanged at $50.6 billion</a>.
<ul>
<li>Third-quarter revenue increased by 20%, excluding the impact of the customer contract expiration, driven by brand and specialty pharmaceutical sales growth from existing and new customers.</li>
<li>Segment profit increased 14% to&nbsp;$662 million&nbsp;in the third quarter, driven by contributions from brand and specialty products, MSO platforms (including GI Alliance), BioPharma Solutions (including Specialty Networks), and positive generics program performance, partially offset by the customer contract expiration.</li>
</ul>
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/05/45140567/cvs-health-partners-with-wegovy-maker-novo-nordisk-hikes-2025-guidance" rel="noreferrer noopener">CVS Health Partners With Wegovy Maker Novo Nordisk, Hikes 2025 Guidance</a>
Revenue for the Global Medical Products and Distribution segment increased 2% to&nbsp;$3.2 billion, driven by volume growth from existing customers.
<ul>
<li>Segment profit increased 77% to&nbsp;$39 million&nbsp;in the third quarter, driven by the beneficial net impact of cost optimization initiatives.</li>
<li>GMPD segment manufactures, sources, and distributes Cardinal Health brand medical, surgical, and laboratory products, as well as distributes medical, surgical and laboratory products known as national brand products</li>
</ul>
Outlook:&nbsp;Cardinal Health raises fiscal year 2025 adjusted EPS from $7.85-$8.00 to $8.05-$8.15 compared to consensus of $7.96.
<ul>
<li>Increased outlook for Pharmaceutical and Specialty Solutions segment profit to 11.5% to 12.5% growth, from 10% to 12% growth previously.</li>
<li>Narrowed outlook for GMPD segment profit to&nbsp;$130 million&nbsp;to&nbsp;$140 million, from&nbsp;$130 million&nbsp;to&nbsp;$150 million&nbsp;previously.</li>
</ul>
Despite the evolving macro environment conditions, Cardinal Health anticipates double-digit non-GAAP EPS growth in fiscal 2026.
<ul>
<li>The company expects strong segment profit growth in Pharmaceutical and Specialty Solutions.</li>
<li>In the face of the macro uncertainty, the company is updating its expectations for fiscal 2026 GMPD segment profit, which it now expects to be at least consistent with fiscal 2025 segment profit.</li>
<li>The company will continue to assess opportunities and risks and plan to discuss its fiscal 2026 and beyond expectations at its upcoming Investor Day on&nbsp;June 12.</li>
</ul>
Price Action:&nbsp;CAH stock is trading 2.30% higher at $144.53 at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/health-care/25/05/45140102/potential-tariff-bites-into-becton-dickinson-2025-profit-outlook-company-will-invest-2-5-billion-to-boost-us-manufacturing" target="_blank" rel="noreferrer noopener">Potential Tariff Bites Into Becton Dickinson 2025 Profit Outlook, Company Will Invest $2.5 Billion To Boost US Manufacturing</a></li>
</ul>
Photo by deemerwha studio via Shutterstock

Large Cap

Guidance

Health Care

Movers

Cardinal Health Lifts FY25 EPS Outlook, Sees Growth Despite Tariff Risks

Cardinal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) raises FY2025 Adj EPS guidance from $7.85-$8.00 to $8.05-$8.15 vs $7.96 analyst estimate..

Cardinal Health Raises FY2025 Adj EPS Guidance from $7.85-$8.00 to $8.05-$8.15 vs $7.96 Est

Cardinal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) reported quarterly earnings of $2.35 per share which beat the analyst consensus estimate of $2.17 by 8.29 percent. This is a 12.44 percent increase over earnings of $2.09 per share from the same period last year. The company reported quarterly sales of $54.88 billion which missed the analyst consensus estimate of $55.35 billion by 0.86 percent. This is a 0.02 percent increase over sales of $54.87 billion the same period last year.

Earnings Beats

Earnings Misses

Cardinal Health Q3 Adj. EPS $2.35 Beats $2.17 Estimate, Sales $54.88B Miss $55.35B Estimate

AAMI

ABNB

ACCO

ADPT

AGCO

AGIO

ALHC

ALKS

ALNY

ALSN

AMWL

APLE

APTV

ARDX

ARVN

ASND

ASPS

ASUR

ATEC

ATEN

AXTI

BBAI

BIIB

BJRI

BLDR

BMRN

BOOM

BPMC

BRFH

CABO

CARR

CART

CERS

CMLS

COHN

COHU

COLM

COMM

COOK

CRAI

CTRE

CUBE

CWST

DBRG

DINO

DSGR

DUOL

DXCM

ECVT

ELME

Earnings Scheduled For May 1, 2025

UBS analyst Kevin Caliendo maintains Cardinal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) with a Buy and raises the price target from $150 to $160.

UBS Maintains Buy on Cardinal Health, Raises Price Target to $160

Cardinal Health's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) short percent of float has fallen 29.09% since its last report. The company recently reported that it has 4.71 million shares sold short, which is 2.56% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.09 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Cardinal Health Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745251229_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Cardinal Health has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Cardinal Health's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Cardinal Health's peer group average for short interest as a percentage of float is 3.60%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Is the Market Bullish or Bearish on Cardinal Health?

B of A Securities analyst Michael Cherny maintains Cardinal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) with a Buy and raises the price target from $150 to $155.

B of A Securities Maintains Buy on Cardinal Health, Raises Price Target to $155

Contracts

Telix Pharmaceuticals Has Selected Cardinal Health As One Of Its Commercial Radiopharmaceutical Distributors To Supply Finished Unit Doses Of Gozellix, PSMA-PET Imaging Agent For Prostate Cancer In US

Mizuho analyst Steven Valiquette maintains Cardinal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) with a Outperform and raises the price target from $142 to $150.

Mizuho Maintains Outperform on Cardinal Health, Raises Price Target to $150

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>05/16/25</td>
<td>$24.00</td>
<td>$50.5K</td>
<td>2.0K</td>
<td>2.0K</td>
</tr>
<tr>
<td>VKTX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$30.00</td>
<td>$60.2K</td>
<td>2.8K</td>
<td>1.6K</td>
</tr>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/28/25</td>
<td>$320.00</td>
<td>$473.7K</td>
<td>609</td>
<td>602</td>
</tr>
<tr>
<td>HCA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$320.00</td>
<td>$312.3K</td>
<td>43</td>
<td>502</td>
</tr>
<tr>
<td>AKRO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$27.50</td>
<td>$35.0K</td>
<td>2.4K</td>
<td>469</td>
</tr>
<tr>
<td>GERN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>10/17/25</td>
<td>$1.00</td>
<td>$33.7K</td>
<td>413</td>
<td>397</td>
</tr>
<tr>
<td>EWTX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$30.00</td>
<td>$32.2K</td>
<td>5.4K</td>
<td>332</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$230.00</td>
<td>$53.6K</td>
<td>6.9K</td>
<td>295</td>
</tr>
<tr>
<td>CAH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$130.00</td>
<td>$44.2K</td>
<td>2.6K</td>
<td>188</td>
</tr>
<tr>
<td>BMY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$57.50</td>
<td>$64.9K</td>
<td>9.5K</td>
<td>167</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• Regarding PFE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), we observe a call option sweep with neutral sentiment. It expires in 56 day(s) on May 16, 2025. Parties traded 200 contract(s) at a $24.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $50.5K, with a price of $253.0 per contract. There were 2012 open contracts at this strike prior to today, and today 2073 contract(s) were bought and sold. 
• For VKTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>), we notice a put option trade that happens to be bearish, is expiring today. Parties traded 300 contract(s) at a $30.00 strike. The total cost received by the writing party (or parties) was $60.2K, with a price of $201.0 per contract. There were 2865 open contracts at this strike prior to today, and today 1625 contract(s) were bought and sold. 
• Regarding AMGN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), we observe a put option sweep with bullish sentiment. It expires in 7 day(s) on March 28, 2025. Parties traded 600 contract(s) at a $320.00 strike. This particular put needed to be split into 57 different trades to become filled. The total cost received by the writing party (or parties) was $473.7K, with a price of $779.0 per contract. There were 609 open contracts at this strike prior to today, and today 602 contract(s) were bought and sold. 
• Regarding HCA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>), we observe a put option sweep with bearish sentiment. It expires in 27 day(s) on April 17, 2025. Parties traded 474 contract(s) at a $320.00 strike. This particular put needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $312.3K, with a price of $660.0 per contract. There were 43 open contracts at this strike prior to today, and today 502 contract(s) were bought and sold. 
• For AKRO (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKRO#NASDAQ">AKRO</a>), we notice a call option trade that happens to be bearish, is expiring today. Parties traded 20 contract(s) at a $27.50 strike. The total cost received by the writing party (or parties) was $35.0K, with a price of $1750.0 per contract. There were 2499 open contracts at this strike prior to today, and today 469 contract(s) were bought and sold. 
• Regarding GERN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GERN#NASDAQ">GERN</a>), we observe a call option trade with bearish sentiment. It expires in 210 day(s) on October 17, 2025. Parties traded 397 contract(s) at a $1.00 strike. The total cost received by the writing party (or parties) was $33.7K, with a price of $85.0 per contract. There were 413 open contracts at this strike prior to today, and today 397 contract(s) were bought and sold. 
• Regarding EWTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EWTX#NASDAQ">EWTX</a>), we observe a call option sweep with bullish sentiment. It expires in 27 day(s) on April 17, 2025. Parties traded 104 contract(s) at a $30.00 strike. This particular call needed to be split into 21 different trades to become filled. The total cost received by the writing party (or parties) was $32.2K, with a price of $310.0 per contract. There were 5479 open contracts at this strike prior to today, and today 332 contract(s) were bought and sold. 
• For ABBV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), we notice a call option sweep that happens to be bearish, expiring in 91 day(s) on June 20, 2025. This event was a transfer of 198 contract(s) at a $230.00 strike. This particular call needed to be split into 35 different trades to become filled. The total cost received by the writing party (or parties) was $53.6K, with a price of $271.0 per contract. There were 6965 open contracts at this strike prior to today, and today 295 contract(s) were bought and sold. 
• For CAH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>), we notice a call option sweep that happens to be bullish, is expiring today. Parties traded 137 contract(s) at a $130.00 strike. This particular call needed to be split into 14 different trades to become filled. The total cost received by the writing party (or parties) was $44.2K, with a price of $325.0 per contract. There were 2600 open contracts at this strike prior to today, and today 188 contract(s) were bought and sold. 
• Regarding BMY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>), we observe a call option sweep with bearish sentiment. It expires in 91 day(s) on June 20, 2025. Parties traded 116 contract(s) at a $57.50 strike. This particular call needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $64.9K, with a price of $560.0 per contract. There were 9548 open contracts at this strike prior to today, and today 167 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

AKRO

EWTX

GERN

VKTX

10 Health Care Stocks Whale Activity In Today's Session

Editor's Note: This article has been updated to clarify that Elliott Investment Management purchased convertible senior notes of Wolfspeed and MicroStrategy.
Elliott Investment Management made several portfolio moves in the fourth quarter, closing multiple options positions and shaking up the activist firm&#8217;s <a href="https://www.benzinga.com/trading-ideas/long-ideas/25/02/43811538/5-top-tech-stocks-hedge-funds-have-been-bullish-on-in-q4-hint-its-not-nvidia">technology exposure</a>.
According to a new&nbsp;<a href="https://www.sec.gov/Archives/edgar/data/1791786/000101359425000294/xslForm13F_X02/primary_doc.xml" target="_blank" rel="noreferrer noopener">13-F</a>&nbsp;filing with the U.S. Securities and Exchange Commission, Elliott added the following new positions in the fourth quarter:
<ul>
<li>Wolfspeed Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOLF#NYSE">WOLF</a>) 0.25% and 1.875% convertible senior notes</li>
</ul>
<ul>
<li>NVIDIA Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) put options</li>
</ul>
<ul>
<li>SPDR Select Sector Fund Industrial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLI#NYSE">XLI</a>) put options</li>
</ul>
<ul>
<li>SPDR S&amp;P Oil &amp; Gas Exploration &amp; Production (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOP#NYSE">XOP</a>) put options</li>
</ul>
Here's a look at all of the positions Elliott added to during the fourth quarter:
<ul>
<li>Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) increased by 369%</li>
</ul>
<ul>
<li>MicroStrategy Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) increased convertible senior notes by 200%</li>
</ul>
<ul>
<li>CorMedix Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRMD#NASDAQ">CRMD</a>) increased by 85%</li>
</ul>
<ul>
<li>HDFC Bank Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HDB#NYSE">HDB</a>) increased by 6%</li>
</ul>
Here&#8217;s a look at all of the positions Elliott closed during the fourth quarter:
<ul>
<li>Catalent Inc (CTLC) </li>
</ul>
<ul>
<li>Cardinal Health Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>)</li>
</ul>
<ul>
<li>Unity Software Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/U#NYSE">U</a>)</li>
</ul>
<ul>
<li>BILL Holdings Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BILL#NYSE">BILL</a>)</li>
</ul>
Elliott closed out of calls in several names including Arm Holdings, American Airlines and Alaska Air Group. The firm also closed multiple put positions including Equinix, Hyatt Hotels and Host Hotels.
Here's a look at all of the positions Elliott trimmed during the fourth quarter:
<ul>
<li>ICON Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) decreased by 62%</li>
</ul>
<ul>
<li>RingCentral Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RING#NYSE">RING</a>) decreased by 55%</li>
</ul>
<ul>
<li>NRG Energy Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRG#NYSE">NRG</a>) decreased by 50%</li>
</ul>
<ul>
<li>Confluent Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CFLT#NASDAQ">CFLT</a>) decreased by 37%</li>
</ul>
<ul>
<li>Southwest Airlines Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUV#NYSE">LUV</a>) decreased by 2%</li>
</ul>
The above information does not include call or put options that were added to or trimmed&nbsp;during the quarter.
This information was gathered using comparison tools from&nbsp;<a href="https://13f.info/13f/000101359425000294/compare/000101359424000968" target="_blank" rel="noreferrer noopener">13f.info</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/02/43811538/5-top-tech-stocks-hedge-funds-have-been-bullish-on-in-q4-hint-its-not-nvidia">5 Top Tech Stocks Hedge Funds Have Been Bullish On In Q4 (Hint: It&#8217;s Not Nvidia)</a></li>
</ul>
This illustration was generated using artificial intelligence via Midjourney.

Hedge Funds

BILL

CFLT

CRMD

ICLR

MSTR

RING

WOLF

Elliott Investment Management Bets Against Nvidia In Q4 (CORRECTED)

The year 2024 was an extremely fruitful one for investors, with the S&amp;P 500 Index soaring in excess of 20%. Adding to the optimism, data pertaining to manufacturing activity was impressive in January. The Institute of Supply Management&#39;s survey, released earlier this month, showed that its manufacturing PMI jumped to 50.9 in January, the highest reading since September 2022. The significant decline in inflation followed by the Fed&#39;s rate cuts has gone a long way in boosting the demand scenario. Donald Trump&#39;s return as President has also added to the optimism.
Given this encouraging backdrop, investors would do well to keep a tab on broker-friendly stocks like Dana DAN, Camping World CWH, ABM Industries ABM, Cardinal Health CAH and DXC Technology DXC.
We have designed a screen to shortlist stocks based on improving broker recommendations and upward revisions in earnings estimates over the past four weeks. Also, since the price/sales ratio is a strong complementary valuation metric in the presence of broker information, it has been included. The price/sales ratio takes care of the company&#39;s top line, making the strategy a well-rounded one.
<h2>Screening Criteria</h2>
# (Up- Down Rating)/ Total (4 weeks) =Top #75&nbsp;(This gives the list of the top 75 companies that have witnessed net upgrades over the last 4 weeks).
% change in Q (1) est. (4 weeks) = Top #10&nbsp;(This gives the top 10 stocks that have witnessed earnings estimate revisions over the past 4 weeks for the upcoming quarter).
Price-to-Sales = Bot%10&nbsp;(The lower the ratio, the better. Companies meeting this criterion are in the bottom 10% of our universe of over 7,700 stocks with respect to this ratio).
Price greater than 5&nbsp;(as a stock trading below $5 will not likely create significant interest for most of the investors).
Average Daily Volume greater than 100,000 shares over the last 20 trading days&nbsp;(Volume has to be significant to ensure that these are easily traded).
Market value ($ mil) = Top #3000&nbsp;(This gives us stocks that are the top 3000 in terms of market capitalization).
Com/ADR/Canadian= Com&nbsp;(This takes out the ADR and Canadian stocks).
Here are five of the 10 stocks that made it through the screen:
Dana&nbsp;is a provider of power conveyance and energy-management solutions for vehicles and machinery in North America, Europe, South America and the Asia Pacific. The company is headquartered in Maumee, OH.
DAN currently sports a Zacks Rank #1 (Strong Buy). The Zacks Consensus Estimate for DAN&#39;s 2025 earnings has been revised 15.4% upward over the past 60 days.
You can see&nbsp;<a href="https://www.zacks.com/stocks/buy-list/?ADID=zp_1link&amp;ICID=zpi%20_1link" target="_blank">the complete list of today&#39;s Zacks #1 Rank stocks here</a>
Camping World Holdings, currently carrying a Zacks Rank #2 (Buy), retails recreational vehicles and related products and services in the United States. It operates through two segments, Good Sam Services and Plans and RV and Outdoor Retail.
The company aims to capitalize on the current favorable environment for dealership mergers and acquisitions. CWH outpaced the Zacks Consensus Estimate for earnings in two of the last four quarters and missed the mark in the other two. The average beat was 16.6%.
New York-based&nbsp;ABM Industries&nbsp;is a provider of integrated facility solutions in the United States and other countries. ABM currently carries a Zacks Rank #2. The company has an impressive surprise history, with its earnings surpassing the Zacks Consensus Estimate in each of the last four quarters, the average beat being 11.6%.
ABM launched ELEVATE in 2021. It is designed to drive organic growth and modernize its digital ecosystem. The acquisition of RavenVolt in 2022 strengthened the company&#39;s presence in EV infrastructure and power solutions.
Cardinal Health is a nation-wide drug distributor and provider of services to pharmacies, healthcare providers and manufacturers. CAH has two reporting segments &mdash; Pharmaceutical and Specialty Solutions, Global Medical Products and Distribution and Others.
Cardinal Health has an expected earnings growth rate of 5.3% for the current year. The Zacks Consensus Estimate for current-year earnings has improved 1.4% over the last 60 days. CAH currently carries a Zacks Rank #2.&nbsp;
DXC Technology&nbsp;is benefiting from strength in the digital business and partnerships, which are helping it expand in the cloud computing space. DXC is implementing robust cost-saving measures to enhance its financial performance.
Over the past 60 days, the Zacks Consensus Estimate for DXC Technology&#39;s current-year earnings has increased 5.4%. DXC&#39;s earnings surpassed estimates in the last four quarters, the average beat being 22.2%. The company currently carries a Zacks Rank #3 (Hold).
You can get the rest of the stocks on this list by signing up now for a 2-week free trial to the Research Wizard stock picking and backtesting software. You can also create your own strategies and test them first before making investments.
The Research Wizard is a great place to begin. It&#39;s easy to use. Everything is in plain language. And it&#39;s very intuitive. Start your Research Wizard trial today. And the next time you read an economic report, open up the Research Wizard, plug your finds in, and see what gems come out.
<a href="https://woas.zacks.com/zcom/researchwizard/tools3.php?site=ZCOM_RW_IND_ARTICLES">Click here to sign up for a free trial to the Research Wizard today</a>.
Disclosure: Officers, directors and/or employees of Zacks Investment Research may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material. An affiliated investment advisory firm may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material.
Disclosure: Performance information for Zacks&#39; portfolios and strategies are available at:&nbsp;<a href="https://www.zacks.com/performance">https://www.zacks.com/performance</a>
&nbsp;
<h2>Only $1 to See All Zacks&#39; Buys and Sells</h2>
We&#39;re not kidding.
Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent.
Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like&nbsp;Surprise Trader, Stocks Under $10, Technology Innovators,and more, that closed 256 positions with double- and triple-digit gains in 2024 alone.
<a href="https://www.zacks.com/registration/ultimatetrader/welcome/eoffer/6328?adid=SYND_BENZ_ZU_ZU_ANALYSTBLOG_259_IND_02182025_2417283&amp;cid=CS-BENZ-FT-analyst_blog|rw-2417283" style="font-weight:bold">See Stocks Now &gt;&gt;</a>
&nbsp;
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. <a href="https://www.zacks.com/registration/pfp/?ALERT=RPT_7BST_LP194&amp;ADID=SYND_BENZ_7BEST_ANALYSTBLOG_259_2417283&amp;cid=CS-BENZ-FT-analyst_blog|rw-2417283" target="_blank">Click to get this free report</a>

&nbsp; 
<a href="https://www.zacks.com/registration/pfp?ALERT=ZER_LINK&amp;t=CAH&amp;ADID=SYND_BENZ_TCK_ANALYSTBLOG_259_2417283_CAH&amp;cid=CS-BENZ-FT-analyst_blog|rw-2417283">Cardinal Health, Inc. (NYSE: </a><a class="ticker" href="https://www.benzinga.com/stock/cah#NYSE">CAH</a>): Free Stock Analysis Report 
&nbsp; 
<a href="https://www.zacks.com/registration/pfp?ALERT=ZER_LINK&amp;t=ABM&amp;ADID=SYND_BENZ_TCK_ANALYSTBLOG_259_2417283_ABM&amp;cid=CS-BENZ-FT-analyst_blog|rw-2417283">ABM Industries Incorporated (NYSE: </a><a class="ticker" href="https://www.benzinga.com/stock/abm#NYSE">ABM</a>): Free Stock Analysis Report 
&nbsp; 
<a href="https://www.zacks.com/registration/pfp?ALERT=ZER_LINK&amp;t=DAN&amp;ADID=SYND_BENZ_TCK_ANALYSTBLOG_259_2417283_DAN&amp;cid=CS-BENZ-FT-analyst_blog|rw-2417283">Dana Incorporated (NYSE: </a><a class="ticker" href="https://www.benzinga.com/stock/dan#NYSE">DAN</a>): Free Stock Analysis Report 
&nbsp; 
<a href="https://www.zacks.com/registration/pfp?ALERT=ZER_LINK&amp;t=CWH&amp;ADID=SYND_BENZ_TCK_ANALYSTBLOG_259_2417283_CWH&amp;cid=CS-BENZ-FT-analyst_blog|rw-2417283">Camping World (NYSE: </a><a class="ticker" href="https://www.benzinga.com/stock/cwh#NYSE">CWH</a>): Free Stock Analysis Report 
&nbsp; 
<a href="https://www.zacks.com/registration/pfp?ALERT=ZER_LINK&amp;t=DXC&amp;ADID=SYND_BENZ_TCK_ANALYSTBLOG_259_2417283_DXC&amp;cid=CS-BENZ-FT-analyst_blog|rw-2417283">DXC Technology Company. (DXC): Free Stock Analysis Report</a>
<a href="https://www.zacks.com/stock/news/2417283/5-broker-loved-stocks-to-keep-an-eye-on-after-recent-analyst-upgrades?cid=CS-BENZ-FT-analyst_blog|rw-2417283">To read this article on Zacks.com click here.</a>
<a href="https://www.zacks.com/">Zacks Investment Research</a>

Upgrades

Small Cap

5 Broker-Loved Stocks To Keep An Eye On After Recent Analyst Upgrades

Press Releases

Cardinal Health to open new distribution center in Fort Worth, Texas

Cardinal Health Reports Second Quarter Fiscal Year 2025 Results and Raises Fiscal Year 2025 Outlook

Dividends

Cardinal Health Board of Directors Approves Quarterly Dividend

Robert Musslewhite and Sudhakar Ramakrishna to join Cardinal Health Board of Directors

Cardinal Health to Announce Third-Quarter Results for Fiscal Year 2025 on May 1

Telix Announces Cardinal Health for Gozellix Commercial Distribution

Cardinal Health Reports Third Quarter Fiscal Year 2025 Results and Raises Fiscal Year 2025 Outlook

Comments

Cardinal Health

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO